Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response ; volume:167 ; number:2 ; day:18 ; month:3 ; year:2024 ; pages:243 ; date:4.2024
Journal of neuro-oncology ; 167, Heft 2 (18.3.2024), 243, 4.2024
- Urheber
-
Bobholz, Samuel A.
Hoefs, Alisha
Hamburger, Jordyn
Lowman, Allison K.
Winiarz, Aleksandra
Duenweg, Savannah R.
Kyereme, Fitzgerald
Connelly, Jennifer
Coss, Dylan
Krucoff, Max
Banerjee, Anjishnu
LaViolette, Peter S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-024-04641-2
- URN
-
urn:nbn:de:101:1-2406292107217.755141393697
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bobholz, Samuel A.
- Hoefs, Alisha
- Hamburger, Jordyn
- Lowman, Allison K.
- Winiarz, Aleksandra
- Duenweg, Savannah R.
- Kyereme, Fitzgerald
- Connelly, Jennifer
- Coss, Dylan
- Krucoff, Max
- Banerjee, Anjishnu
- LaViolette, Peter S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Immune phenotypes predict survival in patients with glioblastoma multiforme
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Differential expression of microRNAs as predictors of glioblastoma phenotypes
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Immune phenotypes predict survival in patients with glioblastoma multiforme
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Differential expression of microRNAs as predictors of glioblastoma phenotypes
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Immune phenotypes predict survival in patients with glioblastoma multiforme
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Differential expression of microRNAs as predictors of glioblastoma phenotypes
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment